Phase 2 N=225 Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
Myelodysplastic Syndromes
Primary: Event-free Survival — 1440; 1091 days — p=0.015
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome
Primary: Percentage of Participants With Response — 23.5 Percentage of Participants
Phase 2 N=12 Study of Clinical Efficacy and Safety of Tosedostat in MDS
Myelodysplastic Syndrome
Primary: Over All Survival — 15.9 months
N/A N=290 The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
Myelodysplastic Syndromes (MDS)
Primary: Overall Survival — 55; 58 Participants
Phase 3 N=147 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
MDS
Primary: Percentage of Participants With at Least One Red Blood Cell (RBC) Transfusion During the Double-blind Treatment Period — 59.2; 36.1 percentage of participants — p=0.008
Phase 2 N=10 Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
Myelodysplastic Syndrome
Primary: Dosage Determination for IV-infusion of Vosaroxin in Int-2 or High-risk Mds — 200 mg/m^2
Phase 2 N=30 A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndromes · Thrombocytopenia
Primary: Number of Participants With Response Between Weeks 16 and 20 — 11 Participants
Phase 3 N=135 An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome
Myelodysplastic Syndrome
Primary: Overall Response Rate (ORR): Number of Participants Who Achieved Either Complete Remission (CR), Partial Remission (PR), or Marrow Complete Remission (mCR)…
Phase 2 N=67 A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndrome
Primary: The Overall Improvement Rate — 23.3; 22.7; 16.3; 0 Percentage of Participants
Phase 3 N=216 The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome
Primary: Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days — 30.8; 11.9 Percentage of Participants — p=0.0005
Phase 2 N=15 Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes
Primary: Overall Response Rate (ORR) — 12; 0; 0; 0 participants
Phase 4 N=24 Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
Myelodysplastic Syndromes · Iron Overload
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 24; 11 Participants
Phase 2 N=124 Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome · Chronic Myelomonocytic Leukemia
Primary: Participant Responses — 4; 47; 4; 6 Participants
Phase 2 N=19 CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML
Myelodysplastic Syndromes · Secondary Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose of CD8 Depleted Non-engrafting HLA-mismatched Unrelated Donor Lymphocytes Infusion (NE-DLI) — 5 10^7 CD4 cells/kg
Phase 2 N=173 Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
Myelodysplastic Syndrome · Iron Overload
Primary: Number of Participants Reporting Adverse Events — 171 Participants
Phase 3 N=43 A Study of Galunisertib in Participants With Myelodysplastic Syndromes
Myelodysplastic Syndromes
Primary: Percentage of Participants With Hematological Improvement (HI) — 31.7; 0.0 percentage of participants
Phase 2 N=31 A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome
Myelodysplastic Syndromes
Primary: Response to Treatment - Hematologic Improvement or Complete Response — 21 Participants
Phase 2 N=10 A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.
Myelodysplastic Syndromes
Primary: Percentage of Participants With Clinical Response as Measured by the International Working Group (IWG) Criteria for Hematological Improvement — 50.00; 71.43; 100.00…
Phase 2 N=35 Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome (MDS) · Chronic Myelomonocytic Leukemia (CMML)
Primary: Overall International Working Group (IWG) 2006 Response Rate — 0; 2; 19; 14 Participants
Phase 2 N=52 LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes
Primary: Phase I: Maximum Tolerated Dose (MTD) of LBH589 When Given in Combination With Decitabine — 40 mg (level 5b dosing schedule)
Phase 2 N=23 Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)
Myelodysplastic Syndromes
Primary: The Number of Patients With Grade 3 or Higher Serious Adverse Events. — 3 Participants
Phase 1 N=39 A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome
Myelodysplastic Syndrome
Primary: Phase II: Overall Remission Rate (ORR): Number of Participants Who Achieved Complete Remission (CR)+Partial Remission (PR) - as Per International Working Group (IWG)…
Phase 2 N=57 Revlimid in Transfusion Dependent Patients
Myelodysplastic Syndrome
Primary: Response Signature in Transfusion Dependent MDS Patients — 24; 1; 17; 6 Participants
N/A N=62 Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS
Myelodysplastic Syndromes
Primary: Number of Participants With Receipt of Second Transfusion
N/A N=18 Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts
Myelodysplastic Syndromes
Primary: Number of Participants With Marrow Complete Remission (CR) — 3 participants
Phase 2 N=17 Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Leukemia · Leukemia, Myeloid · Monocytic Leukemia
Primary: Clinical Response: Hematological Improvement - Erythroid (HI-E) — 0; 0 participants
Phase 2 N=29 Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
Leukemia
Primary: Overall Response Rate (ORR) — 0; 3 Participants
Phase 2 N=99 A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes
Myelodysplastic Syndrome
Primary: Number of Participants Who Achieved Overall Response — 33 participants
Phase 2 N=28 Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS
Myelodysplastic Syndrome · MDS
Primary: Number of Participants With Erythroid Response — 5 participants
Phase 2 N=25 Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndromes · Myelodysplastic Syndromes
Primary: Number of Patients With Response as Defined by IWG (International Working Group) Criteria for Myelodysplasia — 7; 4; 0; 9 participants